Urinary tract infection (UTI) is among the most common bacterial infections worldwide.
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This study shows the first application of GC-APCI-MS in a clinical setting specifically in the context of urinary tract infection.
Introduction
Urinary Tract Infection (UTI) is among the most common bacterial infections worldwide.
Clinical presentation of UTI is broad: from a mild cystitis to severe pyelonephritis, which can quickly evolve into life-threatening conditions such as urosepsis and multiple organ failure 1, 2 . In a way, a positive bacterial urine culture is the only common denominator which unifies a variety of clinical syndromes under the term 'urinary tract infection' even though almost 20% of women presenting UTI symptoms will have negative urine culture 3, 4 . The understanding of the physiological mechanisms affected by UTI may need modern integrative '-omics' technologies, and metabolomics in particular. Indeed, a few proof of principle studies have demonstrated the feasibility of the metabolomics approaches for the analysis of urines from UTI patients 5, 6 and even demonstrated metabolomics-based routines for uropathogen identification [7] [8] [9] . Each of these studies advocated a specific technological solution but it is well known that the use of different analytical platforms often results in complementary data. Our aim is to create a comprehensive overview of UTI-induced changes in the metabolic patterns of patients' urine by applying several explorative methodologies on a carefully matched selection of patients from a multicentre prospective observational study of UTI 10 . To this end, in our previously published papers, we used wellestablished techniques such as liquid chromatography-mass spectrometry (LC-MS) 11 and nuclear magnetic resonance (NMR) 12 in order to investigate the UTI-induced changes in the metabolite profile.
GC-MS equipped with atmospheric pressure chemical ionization (GC-APCI-MS) has only
recently been included into the toolbox for metabolite analysis. The detection at atmospheric pressure rather than with a vacuum stage (e.g. chemical ionization and electronic impact) has demonstrated its potential in a wide variety of fields ranging from pharmaceutical applications 13 to studies of bacterial metabolism 14 , food [15] [16] [17] [18] [19] and environmental analysis 20 . In this manuscript, we present the results obtained with a recently described GC platform equipped with two detectors running in parallel -namely an atmospheric pressure chemical ionization source -mass spectrometer (GC-APCI-MS) and a flame ionization detector (FID). We applied this platform to the investigation of changes in metabolic profiles of urinary tract infection (UTI) patients which may assist in monitoring the infectious status of the patients.
Results and discussion GC-APCI-MS is a relatively recent addition to the metabolomics' toolbox. A number of publications showing the feasibility of this new technique for non-targeted approach is growing consistently. Yet, to our best knowledge, there is no report demonstrating how it performs in exploratory studies in clinical application. Here we present the first GC-APCI-MS-based explorative investigation of urines from UTI patients. This work is part of a larger study in which we aim to create a comprehensive overview of UTI-induced changes in the metabolic patterns within the urine of these patients. A part of the sample set used for the current study has previously been characterized with two other analytical platforms, namely NMR 12 and LC-MS 11 . Those two studies provided us with complementary pictures of the metabolic changes related to the UTI and the recovery process. NMR has revealed a set of metabolites indicative for the degree of the infection, while the LC-MS study resulted in the identification of O-glycosylated fragments of fibrinogen alpha chain as possible morbidity markers.
Thus, as first step of the data analysis, we performed Principal Component Analysis (PCA) on the entire data set which included subjects' samples and pooled quality control samples (193 samples in total). The PCA score scatter plot in the Supplementary Figure 1 shows the spread of the samples along the first two principal components (out of a total of 24 components) which together cover the 16% of the total variability. We have tested the possible correlation with known source of the analytical variability such as the acquisition block, the order of injection or the influence of the column and we could conclude that these factors have eventually a negligible effect on the entire dataset. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
Page 6 of 30 Analyst

Analyst Accepted Manuscript
Supplementary Figure 2 (A and B) shows the PCA score plots for a model built with the 155 samples, including the controls with no clinical signs of the active infection, the baseline samples of UTI patients (t=0 day) and the follow-up samples -30 days after the day of enrollment (t=30 day)-is shown. No trend related to the infectious status is present in the first two principal components. However, a trend separating the UTI-subjects from UTI-free and recovered patients(t=30 day) is present along the second and the third components.
In the next step, we built two separate PCA models: one for the baseline (UTI patients t=0 days and controls) and one for UTI patients at baseline and at 30 days after the treatment (Supplementary Figure 3 A and B) . Despite a clear visual trend indicating the expected clustering in both PCA models, a fraction of the variance covered by the first two principal components is just 16% that suggests that there is no main trend driving the dataset but a combination of confounders which contribute to the model. Consequently, the statistical quality of the regression models (goodness of fit and prediction power) built on the same selection of samples was poor (data not shown). This observation appears to be contradictory to our previously published reports. However, in comparison to the previous studies, where we restricted our selection to the patients with culture-confirmed febrile E.coli UTI, the current selection includes the subjects with different uropathogens (Table 1 ) in order to mimic the real microbiological incidence that show as main pathogenic source extra intestinal Escherichia coli; this organism is isolated in 80% to 85% of episodes [21] [22] [23] . Thus, with the aim to explore whether the quality of the models is affected by the heterogeneity of the pathogens, we restricted the selection to UTI subjects with E. coli as pathogen. Figure 1A and 1B display the cross-validate score plots of the PLS-DA models respectively for the baseline (UTI patients t=0 days and controls) and for UTI patients at baseline and at 30 days after the treatment. Judging on the basis of the model parameters (R2Y=0.922 and Q2=0.519), the longitudinal (t=0, t=30 day) model (Fig. 1B) is the strongest of the two.
To get an insight into the metabolic differences between the day of enrolment (t=0 day) and after the recovery (t=30 days, we focused on m/z signals with Variable Importance in Projection (VIP) values above 1.5 for the given PLS-DA model. We selected 25 m/z values 18, 24 . If the compounds were not present in the library, de novo identification was performed according to the protocol provided elsewhere 24 . Briefly, the protocol includes the calculation of the molecular ion according to the number of silylated group and fragments (those information can be extrapolated from both MS and MS 2 spectra), the use of accurate mass (mass error < 5ppm) and isotopic distribution. In both cases, library-matched or de novo identification, the possible candidates were compared against urine metabolome database (http://www.urinemetabolome.ca/) and literature data in order to ensure the sustainability of the findings. Table 2 Even a brief overview of the literature shows that all compounds listed in the Table 2 (with exception of the unknowns) are well known constituents of urine 17 . For instance, hyrdroxyhippuric acid is a product of the gut microbiota while 3-(3-hydroxyphenyl)-3-hydroxypropionic acid (HPHPA) was reported as an excretion product of anaerobic bacteria of the Clostridium genus 25 .
Another interesting compound is inositol. There is no single source for urinary inositol and its isomers. A fraction of myo-inositol has a dietary origin but substantial part of the pool is synthetized de novo. Under normal conditions, up to 98% of myo-inositol is reabsorbed in the renal tubules. Consequently, increased concentrations of myo-inositol could be considered as an indication of ongoing pathological changes in the renal system: increased concentrations of urinary myo-inositol were reported for patients with diabetes and renal failure [26] [27] [28] . For our case myo-inositol is interesting because its alteration during recovery from UTI would eventually be related not to the bacterial metabolism but to the renal function.
Lactose and lactate are very well known markers of the bacterial metabolism: the ability of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Analyst Accepted Manuscript E.coli to metabolize lactose to lactate was an essential part in discovery of the operons 29 .
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Recently Gupta et al. developed a NMR-based method for the selective identification and quantification of the E. coli colonies in urine of UTI patients using the conversion of lactose to lactate. In their procedure, the authors incubated the infected urine samples with the substrate for 6 hours and after that they could measure a decreased intensity of lactose and an increased intensity of lactic acid 8 . Figure Since some of the classifiers seem to be indicative for the presence of pathogens, we tried to build a model for prediction of the infectious status. To this end, we selected cultureconfirmed febrile E.coli UTI subjects who presented samples at both time point (a total of 50 samples) and we built a PLS-DA model which showed comparable statistical values presented for the model in Figure 1B (Supplementary Figure 5) . We used this last model as basis to predict the outcome of the remained UTI t=0 samples at baseline which included the rest of UTI t= 0 day with positive E.coli urine culture (that did not have the sample at t=30 day) as well as the rest of the other pathogen. The results of the prediction, reported in Table   3 , confirm that the so built model has a good sensitivity for E.coli urine samples (75%) while the prediction fails for the majority of the urine contaminated with other pathogen regardless Another important parameter that characterizes UTI is the bacterial load in urine. Thus we built a PLS-regression model using urinary bacterial load (CFU/ml) as a response variable.
The plots shows the classification of the samples ( Figure 3A) is most of the time in agreement with the bacterial load ( Figure 3B ). The m/z and retention time responsible for the correlation of the GC-APCI-MS data and the bacterial count were chosen on the basis of the corresponding VIP values. The list of these variable is reported in Table 4 . This table show a number of unknown compounds and some sugar which were not rising with the previous models. In addition, with this model we can detect the effect of the exogenous compounds such as paracetamol metabolites (paracetamol glucoronide). However on this data matrix, the influence of such compounds was much less pronounced than in both previous reports. The spectra of the identified and unknown compounds are shown in
Citrate is another 'simple' metabolite with a complex functional network. Citrate is often solely considered as one of the intermediates of the TCA cycle. However, as a constituent of body fluids, it plays a different but equally important role in the regulation of homeostasis.
The three carboxylic groups of a citrate molecule may form complexes with metal ions and/or other divalent cations; as such, citrate has been implicated in the control of renal stone formation by forming soluble complexes with calcium 30 . For many years, citrate excretion in urine is used for the assessment of the renal function: for example, reduction of urinary citrate, which we observed for UTI patients at t=0 days, is an alerting signal for pathological changes in the renal metabolism. There are multiple reports showing the decrease of the urinary citrate in nephrolithiasis 31 , glomerulonephritis 32 and more recently in infectious diseases 12, 33 .
Thus, the results obtained with our GC-APCI-MS platform are in line with previous findings and biological meaningful. However there are a few points to improve such as the limited identification. Table 2 and 4 show a considerable number of unknown compounds. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60
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In some cases we failed in identifying compounds de novo; even though we had MS and MS patients who presented with a diagnosis of febrile UTI, were considered for enrolment in the study. The study was approved by the local ethics committees and all patients gave written Analyst Accepted Manuscript informed consent. Inclusion criteria and exclusion criteria have been described in detail elsewhere 34, 35 . In short, patients of 18 years or older, with fever and presenting at least one symptom of UTI (dysuria, increased frequency of urination, perineal pain, flank pain or costovertebral tenderness) and a positive nitrite dipstick test or a positive leukocyte esterase dipstick test were enrolled. Exclusion criteria were current treatment for urolithiasis or hydronephrosis, pregnancy, hemo-or peritoneal dialysis, a history of kidney transplantation or known presence of polycystic kidney disease. Details with respect to empiric therapy and follow-up are provided elsewhere 10 . Urine samples were collected at enrolment as baseline samples (t=0). After four and thirty days (t=30) urine samples of the same patients were collected for follow-up. At all the time points, clean midstream-catch urine samples were cultured and analyzed using standard microbiological methods. A positive urine culture was defined as bacterial growth of over 10 3 colony-forming units per ml. Within 2 hours after collection all samples were stored at -80° C until further analysis.
For the current study, a group of 67 subjects with culture-confirmed bacteria in the urine was selected from a database of approximately 700 subjects. Samples from volunteers without UTI or symptoms of another infection were taken as controls. Baseline characteristics of the samples are presented in the Table 1 . The study design includes the control samples and samples of UTI patients collected at baseline (t=0 days) as well as patient follow up samples collected after the antibiotic treatment (t=30 days). In this last point of the sampling, the subjects did not show any sign of active ongoing infection.
Sample preparation. Urine samples were prepared according to a reference method with minor modifications 36 . Briefly, 100 μl of urine were incubated with 20 Units of urease in 100 μl of water for 45 minutes at 37 ºC to deplete the excess of urea. Protein precipitation was carried out by adding 300 μl of cold methanol and by incubation for 10 min on ice.
After centrifugation at 19.600g for 10 min, 100 μl of the supernatant was transferred to a GC/MS vial and evaporated to dryness. All the samples were stored at -80 ºC until the moment of the GC analysis. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60
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The samples were derivatized online with a double step reaction. Firstly, we added 50 μl of methoxyamine (20 mg/ml in pyridine) and incubated for 1 hour at 60 ºC. Secondly, we added 50 µl of MSTFA and incubated at 60 ºC for 40 minutes. Subsequently, we added 100 μl of toluene.
Hundread μl of each urine sample were pooled, aliquoted and then used as quality control which were prepared with the same protocol. The transfer line to the mass spectrometer was kept at 300 ºC. The APCI source was operated in positive mode. The temperature and the flow rate of the dry gas (nitrogen) were 300°C and 2.00 l/min, respectively. The APCI vaporizer temperature was 300 °C; the pressure of the nebulizer gas (nitrogen) was set to 3.5 bar and the voltage of the corona discharge needle was +2000 nA. Capillary voltage was set to -1000V and the end-plate offset to -500 V. The source and detector parameters have been set in order to achieve a minimal resolution of 40000.
GC-APCI-MS-FID
A maXis 4G (Bruker Daltonics, Bremen, Germany), an orthogonal-accelerated Qq-ToF mass spectrometer, was used as mass analyzer. The spectra were acquired in a mass range from m/z 100-1000 at an acquisition rate of 1Hz. Before each chromatographic run, a tune mix solution was used as external calibrant and injected in Flow Injection mode. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Analyst Accepted Manuscript The FID flows and temperature were set as follows: front detector 300 °C, hydrogen flow:
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40 ml/min and air flow: 370 ml/min.
Statistical analysis. The GC-MS data files were exported as mzXML files. The peak picking was performed with XCMS package (The Scripps Research Institute, La Jolla, USA) using the following commands: method="centWave", scanrange=c(480,2900), ppm=10, snthresh=10, peakwidth=c(5,15), prefilter=c(3,3000), noise=3000. The grouping was performed using band width=10, minfrac=1, minsamp=37. The final data matrix was normalized with Probabilistic Quotient Normalization algorithm 37 . The generated data matrix was imported to the SIMCA-P 13.0 software package (Umetrics, Umeå, Sweden).
The data were mean centred, unit variance-scaled and Power transformed prior to the statistical analysis. The validity and the degree of overfitting of the PLS-DA models were checked using a 20 permutations test.
To identify metabolites of interest, rational chemical formulas were generated based on internally calibrated monoisotopic masses within 2 mDa mass error, using the SmartFormula tool within the DataAnalysis software package (Bruker Daltonics).
Conclusion
Here, we have presented the first application of an explorative metabolomics study on a GC- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Analyst Accepted Manuscript 14 overview of UTI-induced changes in urine, this study points some physiological marker of the febrile UTI status. In accordance with the NMR study, this approach has revealed a number of compounds that might be associated with bacterial activity. On the other side, this also shows some unique feature that needs to be investigated further for eventual association to the physiological status. Although obviously no firm biological conclusions can yet be drawn, this study nevertheless has provided findings which may further on contribute to the understanding of the physiological mechanisms underlying the progression of UTI. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Analyst Accepted Manuscript Haemolytic Streptococcus Group B 2
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Enterococcus faecalis 3
Klebisella pneumoniae 4
Pseudomonas aeruginosa 2
Staphylococcus aureus 1
Staphylococcus saprophyticus 2
Klebsiella oxytoca 1
Aerococcus urinae 1
Acinetobacter species 1
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Supplementary Figure 5 . Cross-validates score plot of a PLS-DA built on UTI subjects (E.coli) who presented samples at both time point t=0 and t=30 days (50 samples in total).
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